Correlation between Her2/Neu and Histopatholoical Finding among Sudanese Female Breast Cancer Patients

Hamed, Riyadh; Abdelbadie, Ahmed; Osman, Ibrahim; Eltayeb, El khazin; Omer, Husam Eldein

doi:10.18488/journal.9/2015.2.4/9.4.62.69

Cited by 1 publication

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the correlation of Her2/neu with GIST mitotic count, risk grade, and tumor size, it is found that Her2/neu is more expressed in mitotically active, high-grade, large-sized tumors (>5 cm in diameter and mitotic count >4/50 HPF) with a significant predictive value (.00, .04, and .001, respectively); these are in accordance with the findings of many research works which found a strong association between Her2/neu staining and advanced stage and grade of breast cancer. 23-26…”

Section: Discussionmentioning

confidence: 99%

“…13,20 Most of our cases are in high-risk category; this result is similar to a study by Orosz et al 20 Regarding the correlation of Her2/neu with GIST mitotic count, risk grade, and tumor size, it is found that Her2/neu is more expressed in mitotically active, high-grade, large-sized tumors (>5 cm in diameter and mitotic count >4/50 HPF) with a significant predictive value (.00, .04, and .001, respectively); these are in accordance with the findings of many research works which found a strong association between Her2/neu staining and advanced stage and grade of breast cancer. [23][24][25][26] The relationship between Her2 expression and relapse in patients with GIST was very interesting; Her2/neu was expressed positively in all cases who experienced relapse within 2 years of follow-up, whereas it was positive in only 10% of cases who showed no relapse. This correlation was highly significant (P = .00).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of Her2/neu Expression in Gastrointestinal Stromal Tumors: Immunohistochemical Study

El-Aziz

Ibrahim

Abd-Elmoghny

et al. 2017

Cancer�Growth�Metastasis

View full text Add to dashboard Cite

Background:Gastrointestinal stromal tumor (GIST) is a relatively rare type of neoplasms. In Egypt, it represents 2.5% of gastrointestinal tumors and 0.3% of all malignancies. Most of the GISTs develop in the stomach.Aim:To reveal the significance of Her2/neu immunohistochemical expression in GIST and its correlation with other histopathologic parameters and tumor relapse after regular follow-up.Patients and methods:This study is a retrospective and prospective cohort. It included 32 patients with GISTs, who were resectable with no distant metastasis. Immunohistochemical staining by Her2/neu was performed after complete surgical resection of the tumors with preservation of the pseudocapsule.Results:In total, 53.1% of cases were men and 46.9% women. Tumors were classified into low-risk (25%), intermediate-risk (21.9%), and high-risk groups (53.1%). Her2/neu expression was negative in 56.3% of GISTs and positive in 43.7%. Its expression was significantly correlated with risk grade (P = .04), tumor size (P = .001), mitotic count (P = .00), and increased risk of relapse (P = .00). Furthermore, tumor relapse was significantly correlated with the tumor mitotic counts (P = .00). Using kappa agreement test, it showed that 4 mitotic counts/50 high-power fields (HPF) was the cutoff value with which the tumor might be associated more with relapse, with 83% sensitivity, 70% specificity, and P value of .003.Conclusions:Her2/neu might be used as an independent prognostic marker for tumor recurrence after complete resection of GIST, and the cutoff value of mitotic count that might predict tumor relapse is 4/50 HPF. However, more clinical studies with greater number of cases with fluorescent in situ hybridization integration are recommended.

show abstract

Section: Discussionmentioning

confidence: 99%